Introduction
The Philadelphia chromosome (Ph) has been considered the hallmark of chronic myeloid leukemia (CML). However in 10% of the cases the t(9;22)(q34;qll), cannot be identified, although the molecular rearrangement between BCR and ABL genes is present [1] . These cases are indistinguishable from the Ph-i-cases [1, 2] . In addition, there are some rare cases with a clinical and hematological appearance similar to that of CML but lacking both the Ph chromosome and BCR-ABL rearrangement; these are known as atypical CML (aCML) [3] . The FAB cooperative group has suggested that aCML can be distinguished from CML on a morphological basis. Thus aCML is characterized by the combination of low basophil counts and a percentage of monocytes ranging from 4%-15% with high percentages of immature granulocytes that are markedly dysplastic [4, 5] . Oscier et al. have recently described 10 cases of aCML: all of them presented with features of typical refractory anemia and were only diagnosed as aCML once the disease had evolved. Based on these findings, Oscier et al. have suggested that aCML is more closely related to myelodisplastic syndrome (MDS) than to myeloproliferative disorders [6] . Moreover, two other reports have also described some rare cases of MDS evolving into a myeloproliferative disorder (MPD) [7, 8] . All these cases displayed a common biphasic course, together with leukocytosis, thrombocytosis and poor outcome [6] [7] [8] .
In order to contribute to a more comprehensive characterization of this rare hemopoietic disorder we have analyzed the clinical, hematological and cytogenetic characteristics of a series of 11 cases with aCML.
Patients and methods
Between the years 1992 and 1997 a total of 11 patients were diagnosed as having aCML, according to FAB criteria, at the Hematology Departments of the University Hospitals of Salamanca (Spain) and Ferrara (Italy).
Morphological classification
Hematological evaluation was made following the FAB recommendations [5] . A complete blood count was carried out, with differential WBC count and analysis of dysplastic features. In the bone marrow (BM) aspirates the following parameters were assessed: cellularity, myeloid/erythroid ratio, percentage of blasts, and dysplastic features RH P P P P P P P P P P P Abbreviations: Hb -hemoglobin; WBC -white blood cells count, IG -immature granulocytes; DisER -diserytropoiesis, DisGR -disgranulopoiesis, DisMK dismegakaryopoiesis, 1 = slight; 2 = moderate; 3 = strong; NE -not evaluable RH -red cell hypoplasia, P -present; M -male; F -female. " At time of diagnosis (four months before) the patient had hb. 63 g/dl; WBC: 6 x 10 9 /l and platelets 189 x lo'/l. of granulocytes, megakaryocytes and red cells. In both, peripheral blood and BM, a total of 1000 nucleated cells were analyzed. The dysplasia was scored as 1 (slight), 2 (moderate) and 3 (severe) [9] . Disgranulopoiesis was considered when the following features were observed: (1) granulocytes with a decreased content in granules or giant granules; (2) pseudo-Pelger morphology; (3) ring-shaped nucleus; (4) frequent Dohle bodies [9] .
Chromosome analysis
Bone marrow samples were cultured for 48 hours following standard procedures. At least 25 metaphases were analyzed. The chromosomes were stained by Giemsa, and the karyotypes are described according to ISCN (1995) recommendations [10] .
FISH
Fluorescence in silu hybridization (FISH) studies were carried out as previously described [11] . The BCR-ABL fusion gene was studied with a specific probe following the manufacturer's intructions (Vysis, Stuttgart, Germany). In order to study the 12p region the YAC 964clO, covering ETV6, was labeled with digoxigenin-11-d-UTP, denaturated, preannealed with Cot-1 DNA and hybridized overnight on pretreated and denaturated chromosome spreads. After washing, the probe was detected with two layers of TRITC-conjugated antibodies. In addition, a centromere-specific probe for chromosome 12 was used (CEP12 Spectrum Spectrum Green, Vysis, Stuttgart, Germany) The results were analyzed by counting 200 interphase cells.
RT-PCR amplification
In vitro reverse transcription (RT) of 1 (ig of total RNA to cDNA and RT-PCR amplification of M7m-BCR/ABL fusion transcripts were performed according to the guidelines proposed by Maurer et al. [12] . Table 1 shows the clinical and hematological features of the 11 patients with an aCML. There was no sex predominance (six males and five females). The median age was 65 years (range 16-84 years). All but one case (no. 6) displayed leukocytoses (median WBC was 36 x 10 9 /l; range 6-68 x 10 9 /l). Case no. 6 developed leukocytoses four months after diagnosis and had previously been diagnosed as refractory anemia. All cases had less than 10% of monocytes in the peripheral blood. Seven out of the 11 cases had hemoglobin levels below 120 g/1. Platelet counts were highly variable. Thus, while 4 out of the 11 cases showed thrombocytopenia (< 100 x 10 9 /l), the platelet count was normal in 6 cases, and the remaining patient showed thrombocytosis (732 x 1O 9 /1) ( Table 1) . Regarding bone marrow morphology, 83% of the cases showed granulocytic dysplasia, which was marked in 45% of the cases. Most of the cases [8] had both erythroid and megakaryocytic dysplasia. All patients showed red cell hypoplasia (Table 1) . Case no. 4 showed coarse chromatin clumping.
Results

Clinical and hematological data
Cytogenetic studies
All but two cases (nos. 4 and 10) had an abnormal karyotype. Trisomy of chromosome 8 was found in three cases. Other clonal chromosomal abnormalities included deletions of 5q, 13q, 17p, 12q, and llq as well as an unbalanced translocation between 6p and 8q and an add(21q) ( Table 2) .
FISH studies
All cases were negative for the BCR-ABL fusion gene. The analysis of interphase nuclei did not show a deletion of the ETV-6 gene in any the 11 patients analyzed.
RT-PCR
An M-ABL/BCR or m-ABL/BCR fusion transcript was not detectable in patients 1 and 5, respectively. [15] Interval from diagnosis to therapy Abbreviations: Hy -hydroxyurea; Ida -idarubicin; LD -low-dose; BMT -allogeneic bone marrow transplantation; Mitox -mitoxantrone; NR -no response; CR -complete response; PR -partial response. a In accelerated phase. In chronic phase the karyotype was 46,XX.
Outcome
Ten of the eleven cases were treated with chemotherapy. The remaining case (no. 6) only received supportive therapy. First-line chemotherapy included hydroxyurea in six cases. Intensive chemotherapy (AML-type), including anthracyclines, and intermediate doses of ara-C was used in four cases (Table 2) . Only one patient (no. 5) achieved complete remission and subsequently received an allogeneic bone marrow transplant (BMT). Median survival was 14 months (range 3-56 months) with only 3 out of the 11 patients alive at 3 years (Table 2) . Patients with a normal platelet count and a hemoglobin level higher than 100 g/1 had longer survival (Tables 1 and 2 ).
Discussion
A series of 11 cases with the diagnosis of aCML, according to the FAB criteria, is described. In 1994 the FAB group proposed the criteria for morphological diagnosis of aCML. However, since then few series have been published [2, 6, 13] . Recently Oscier et al. suggested that aCML should be considered as a distinct clinical entity more related to myelodysplastic syndromes (MDS) than to myeloproliferative disorders (MPD) [6] . Our data based on the morphological analysis of peripheral blood and bone marrow would also support the idea that aCML is a distinct entity with intermediate characteristics of both groups of diseases (MDS and MDP).
Some differences between the present series and the cases previously reported can be established. The cases described by Oscier et al. were diagnosed as aCML during the evolution of a previous disease (mostly MDS) [6] . However, in all but one of the present cases the diagnosis of aCML was made at presentation. In addition, the median age reported here, 65 years, is lower than that previously described, 76 years [6, 13] . Moreover, our study includes two cases below 50 years of age. Overall this data suggests that although aCML is a disease of the elderly, it can also be found in middleaged patients.
Regarding the hematological data, the most uniform finding is the presence of leukocytosis. The FAB group have reported that in aCML, mean WBC count is around 100 x 1O 9 /1 [5] . However, our data, as well as the data from other groups, show that these cases usually display lower WBC counts, ranging between 18 x 10 9 /l and 76 x 1O 9 /1 [6] [7] [8] 13] . One of the most relevant characteristics of the differential count is the absence of basophilia, which may be of help for differential diagnosis with CML [4, 7] . In fact, in all but one of the cases published, as well as in our series, the proportion of basophils was less than 2%. Nevertheless, the most striking feature was the presence of marked granulocytic dysplasia; most cases showed an increased proportion of immature granulocytes, which were dysplastic. Severe anemia is significantly less common than it is in MDS. Thus only 54% of our cases showed hemoglobin values below 110 g/1. These results do not concur with those reported by Oscier et al., since all his ten cases showed hemoglobin levels below 110 g/1 [6] . Moreover, in our experience thrombocytopenia (platelet count < 100 x 10 9 /l) is also infrequent (35% of cases) and one patient actually showed thrombocytosis.
The bone marrow shows intermediate MPD/MDS features. A hypercellular bone marrow with a distinct granulocytic hyperplasia resembling myeloproliferative disorders was observed in the majority of our patients. In accordance with other reports, a red cell hypoplasia was present in all cases [4, 6] . This feature is also more frequent in MPD than in MDS, in which an erythroid hyperplasia is commonly found [6] . By contrast, myelo-dysplasia was marked, particularly in the granulocytic lineage, but the red cells and the megakaryocytic lineage were also dysplastic.
Nine of the eleven cases showed chromosomal abnormalities. However, no recurrent karyotypic abnormalities, other than trisomy 8, were identified. This chromosomal change has been described in myeloid disorders, such as acute myeloblastic leukemia, MDS and MPD, but +8 is not specific to any of them. The other chromosomal changes (5q-, 13q-, llq-, 17p-, and abnormalities in 6p) observed in our study have been associated with MDS but may also be present in the evolution of chronic myeloid leukemia, policythemia vera and essential thromobocytemia [14] . Case no. 5 had a translocation involving 8q, as has been described in one case of aCML [15] . However, we did not find cases with t(5;10) which has been described in aCML [16] . Abnormalities on chromosome 12p, with rearrangements ofETV-6 have been found in patients with chronic myeloproliferative disorders such as chronic myelomonocytic leukemia with eosinophilia [17] and Ph-negative/BCR-positive CML [2] . Our results based on cytogenetics and FISH experiments failed to demonstrate an involvement of the ETV-6 gene in patients with aCML.
Regarding outcome, a poor response to therapy and a short survival was observed. These results are in accordance with previously published data [4, 6, 13] in which the survival with aCML is shorter than with CML. In young patients in early phases of the disease aggressive chemotherapy, including BMT, has to be considered.
In summary, aCML is an infrequent and heterogeneous disease, without a cytogenetic marker, exhibiting mixed myelodysplastic and myeloproliferative features and a poor outcome. Patients presenting with leukocytosis and dysplastic features without monocytosis should be considered for this diagnosis.
